ArticleTopics in spinal cord injury rehabilitation2026
Differences in Prescribing Rates of Glucagon-Like Peptide-1 Receptor Agonists Between Spinal Cord Injured and Non-Spinal Cord Injured Individuals: A Retrospective Study.
Article in Topics in spinal cord injury rehabilitation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been effectively used for obesity management, their frequency of use has not been studied specifically in individuals with spinal cord injury (SCI). Objectives: This study aimed to determine if prescribing rates of GLP-1RAs in individuals with obesity differ between those with and without SCI. Design/Methods: This retrospective cohort study was conducted on the TriNetX, LLC platform with de-identified electronic health record data from over 60 US health care organizations. Two cohorts were analyzed for prescribing rates of GLP-1RAs within 5 years of meeting inclusion criteria. One group carried a diagnosis of obesity but not SCI while the other had obesity and SCI. Individuals with a prior history of bariatric surgery or GLP-1RA use were excluded. The 2 cohorts were balanced for age, gender, race, and type 2 diabetes mellitus. Results: In persons with obesity, SCI individuals had lower prescribing rates of GLP-1RAs (odds ratio [OR] 0.67, 95% CI 0.61-0.73) compared with non-SCI individuals. No significant differences in GLP-1RA prescribing rates were noted when comparing complete SCI or incomplete SCI individuals with persons without SCI. Individuals with complete SCI also had lower odds of receiving GLP-1RA prescriptions (OR 0.71, 95% CI 0.52-0.96) compared with incomplete SCI individuals. Conclusion: GLP-1RA prescribing rates are significantly lower in individuals with obesity and any degree of SCI compared with non-SCI individuals. Future studies will help elucidate factors that influence prescribing patterns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.